Literature DB >> 2180202

Antibody response of the ovine lymph node to experimental infection with an ovine abortion strain of Chlamydia psittaci.

H S Huang1, T W Tan, D Buxton, I E Anderson, A J Herring.   

Abstract

After primary infection with Chlamydia psittaci in the draining area of the popliteal lymph node, viable organisms could be isolated from the efferent lymph only before the primary immune response developed. The lymph antibody response, as assayed by the complement fixation and immunofluorescence (IF) antibody tests, showed a rise in titre that peaked approximately 2 weeks after infection. Immunoblotting revealed that antibodies produced during this period were predominantly directed against the major outer membrane protein (MOMP). In secondary infection of convalescent sheep, an elevated IF antibody titre, already present in the lymph and blood, could not be boosted. Viable organisms could not be isolated from these sheep. Antibodies produced reacted to 12-14 bands in the immunoblot profile including the MOMP band. These potentially immunoprotective antigens, particularly MOMP, should be considered as useful candidates for an improved vaccine against ovine enzootic abortion, in further investigations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2180202     DOI: 10.1016/0378-1135(90)90006-h

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  2 in total

1.  Antibody responses to recombinant protein fragments of the major outer membrane protein and polymorphic outer membrane protein POMP90 in Chlamydophila abortus-infected pregnant sheep.

Authors:  Morag Livingstone; Gary Entrican; Sean Wattegedera; David Buxton; Iain J McKendrick; David Longbottom
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

2.  Protection of sheep against Chlamydia psittaci infection with a subcellular vaccine containing the major outer membrane protein.

Authors:  T W Tan; A J Herring; I E Anderson; G E Jones
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.